Aliases & Classifications for Oligohydramnios

MalaCards integrated aliases for Oligohydramnios:

Name: Oligohydramnios 12 29 52 42 14 69
Oligohydramnios - Delivered 12 69
Oligohydramnios, Antepartum Condition or Complication 69
Antepartum Oligohydramnios 12
Delivered Oligohydramnios 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12215
ICD10 33 O41.0 O41.00
ICD9CM 35 658.0
MeSH 42 D016104
NCIt 47 C92839
UMLS 69 C0079924

Summaries for Oligohydramnios

Disease Ontology : 12 A placenta disease that is characterized by a deficiency of amniotic fluid sometimes resulting in an embryonic defect through adherence between embryo and amnion.

MalaCards based summary : Oligohydramnios, also known as oligohydramnios - delivered, is related to renal tubular dysgenesis and potter's syndrome, and has symptoms including morning sickness An important gene associated with Oligohydramnios is PKHD1 (PKHD1, Fibrocystin/Polyductin), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and Peptide hormone metabolism. The drugs Warfarin and Tocopherol have been mentioned in the context of this disorder. Affiliated tissues include lung, placenta and bone, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 72 Oligohydramnios is a condition in pregnancy characterized by a deficiency of amniotic fluid. It is the... more...

Related Diseases for Oligohydramnios

Diseases related to Oligohydramnios via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
id Related Disease Score Top Affiliating Genes
1 renal tubular dysgenesis 31.9 ACE AGT AGTR1 REN
2 potter's syndrome 11.7
3 twin-to-twin transfusion syndrome 11.0
4 bilateral renal agenesis dominant type 10.8
5 polycystic kidney disease 4, with or without hepatic disease 10.8
6 situs inversus totalis with cystic dysplasia of kidneys and pancreas 10.8
7 urethral obstruction sequence 10.8
8 hypothyroidism due to iodide transport defect 10.7 ACE REN
9 primary hyperoxaluria 10.7 ACE REN
10 congenital anomalies of kidney and urinary tract 2 10.7
11 fetal indomethacin syndrome 10.7
12 renal hypodysplasia/aplasia 1 10.7
13 meckel syndrome 1 10.7
14 potter syndrome type 1 10.7
15 renal dysplasia-limb defects syndrome 10.7
16 trisomy 2 mosaicism 10.7
17 multiple pterygium syndrome, lethal type 10.7
18 atrial septal defect 7, with or without av conduction defects 10.7 ACE REN
19 mody, type ii 10.7 ACE REN
20 hypodontia of incisors and premolars 10.7 ACE REN
21 listeriosis 10.7 ACE REN
22 non-congenital cyst of kidney 10.7 ACE REN
23 pelizaeus-merzbacher-like disease 10.7 ACE AGT
24 voyeurism 10.6 ACE REN
25 hypoaldosteronism, congenital, due to cmo ii deficiency 10.6 AGT REN
26 myopia 10.5 ACE REN
27 small cell lung cancer, adult 10.5 CHRNA1 CHRND
28 pyogenic arthritis, pyoderma gangrenosum and acne 10.4 ACE REN
29 complete cryptophthalmia 10.4 CHRNA1 CHRND
30 familial isolated pituitary adenoma 10.4 AGT AGTR1
31 mental retardation cataracts calcified pinnae myopathy 10.4 AGT AGTR1
32 cystinosis 10.4 ACE AGT REN
33 pulmonary valve insufficiency 10.4 ACE REN
34 craniosynostosis 7 10.4 ACE AGT REN
35 microphthalmia, isolated, with coloboma 7 10.4 ACE REN
36 temple syndrome 10.3 CHRND CHRNG
37 cystic fibrosis and congenital absence of the vas deferens 10.3 AGTR1 PKHD1 REN
38 clitoris cancer 10.3 ACE AGTR1 REN
39 idiopathic juxtafoveal retinal telangiectasia 10.3 ACE AQP1
40 broad ligament malignant neoplasm 10.3 ACE AGTR1 REN
41 lymphadenitis 10.3 ACE AGTR1 REN
42 renal clear cell carcinoma 10.3 ACE AGTR1 REN
43 prostate neuroendocrine neoplasm 10.3 ACE AGTR1 REN
44 cataract, autosomal dominant congenital 4 10.3 ACE AGT AGTR1
45 potato nose 10.2 ACE AGT AGTR1
46 aortopulmonary window 10.2 ACE AGT AGTR1
47 trichinosis 10.2 ACE AGT AGTR1
48 retinitis pigmentosa 17 10.2 ACE AGT AGTR1
49 laryngostenosis 10.2 ACE AGT AGTR1
50 joint disorders 10.2 ACE AGT AGTR1

Graphical network of the top 20 diseases related to Oligohydramnios:



Diseases related to Oligohydramnios

Symptoms & Phenotypes for Oligohydramnios

UMLS symptoms related to Oligohydramnios:


morning sickness

MGI Mouse Phenotypes related to Oligohydramnios:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.02 ACE AFP AGT AGTR1 AQP1 AQP3
2 cardiovascular system MP:0005385 9.92 SERPINH1 ACE AGT AGTR1 AQP1 AQP3
3 growth/size/body region MP:0005378 9.91 ACE AGT AGTR1 AQP1 AQP3 CHRNG
4 mortality/aging MP:0010768 9.9 CHRNA1 CHRNG PKHD1 REN SERPINH1 ACE
5 nervous system MP:0003631 9.56 AGT AGTR1 AQP1 CHRNA1 CHRNG PKHD1
6 renal/urinary system MP:0005367 9.17 ACE AGT AGTR1 AQP1 AQP3 PKHD1

Drugs & Therapeutics for Oligohydramnios

Drugs for Oligohydramnios (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4 81-81-2 6691 54678486
2 Tocopherol Approved, Nutraceutical Phase 4
3
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
4 Vitamins Phase 4
5 Anticoagulants Phase 4
6 Coagulants Phase 4
7 Antioxidants Phase 4,Phase 2,Phase 3
8 Protective Agents Phase 4,Phase 2,Phase 3
9 Tocopherols Phase 4
10 Tocotrienols Phase 4
11
Coumarin Experimental, Nutraceutical Phase 4 91-64-5 323
12 Omega 3 Fatty Acid Nutraceutical Phase 4
13 Tocotrienol Investigational, Nutraceutical Phase 4 6829-55-6
14
Dinoprostone Approved Phase 3 363-24-6 5280360
15
Isosorbide Dinitrate Approved Phase 2, Phase 3 87-33-2 6883
16
Nitric Oxide Approved Phase 2, Phase 3 10102-43-9 145068
17
Oxytocin Approved, Vet_approved Phase 3 50-56-6 439302 53477758
18 Oxytocics Phase 3
19 Anti-Asthmatic Agents Phase 2, Phase 3
20 Autonomic Agents Phase 2, Phase 3
21 Bronchodilator Agents Phase 2, Phase 3
22 diuretics Phase 2, Phase 3
23 Endothelium-Dependent Relaxing Factors Phase 2, Phase 3
24 Isosorbide Phase 2, Phase 3
25 isosorbide-5-mononitrate Phase 2, Phase 3
26 Natriuretic Agents Phase 2, Phase 3
27 Neurotransmitter Agents Phase 2, Phase 3
28 Nitric Oxide Donors Phase 2, Phase 3
29 Peripheral Nervous System Agents Phase 2, Phase 3
30 Respiratory System Agents Phase 2, Phase 3
31 Vasodilator Agents Phase 2, Phase 3
32
Misoprostol Approved 59122-46-2 5282381
33
Menthol Approved 2216-51-5 16666
34
Adenosine Approved, Investigational 58-61-7 60961
35
Pertuzumab Approved 145040-37-5, 380610-27-5 2540
36
Trastuzumab Approved, Investigational 180288-69-1 9903
37
Estradiol Approved, Investigational, Vet_approved 50-28-2 5757
38
Indomethacin Approved, Investigational 53-86-1 3715
39
Cholecalciferol Approved, Nutraceutical 67-97-0 6221 10883523 5280795
40
Ergocalciferol Approved, Nutraceutical 50-14-6 5280793
41
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
42 Bone Density Conservation Agents
43 Calcium, Dietary
44 Ergocalciferols
45 Micronutrients
46 Trace Elements
47 Liver Extracts
48 Antacids
49 Anti-Ulcer Agents
50 Gastrointestinal Agents

Interventional clinical trials:

(show all 25)

id Name Status NCT ID Phase Drugs
1 Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term Completed NCT02581774 Phase 4
2 Warfarine in Unexplained Oligohydramnios Completed NCT01569035 Phase 4 warfarin
3 Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial Completed NCT01990690 Phase 4 anti oxidant omega 3
4 Amnioinfusion Initiative Unknown status NCT00787163 Phase 3
5 Induction of Labor in Oligohydramnios Unknown status NCT00815542 Phase 3 prostaglandins E2
6 Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses Unknown status NCT00127946 Phase 3
7 Nitric Oxide Donors for Treatment of Isolated Oligohydramnios Completed NCT02712125 Phase 2, Phase 3 isosorbide mononitrate;Placebo
8 Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies Recruiting NCT02907060 Phase 3 Pharmacological cervical ripening
9 Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction Not yet recruiting NCT02684305 Phase 3 Administration of Propess;Intravenous oxytocin infusion
10 Alterations of the Uteroplacental and Fetal Pulmonary Circulation Following Amnioinfusion Unknown status NCT01258725 Phase 1
11 Vitamin D Treatment and Hypocalcemic Pregnant Women Unknown status NCT02021864 vitamin D3 50,000 unit;prenatal multivitamin
12 A Screening Strategy for Q Fever Among Pregnant Women Unknown status NCT01095328
13 İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? Unknown status NCT01906567
14 Studying Fetal Breathing Patterns Completed NCT00066976
15 Foley Catheter Versus Vaginal Misoprostol for Cervical Ripening and Induction of Labor Completed NCT01140971 Misoprostol
16 Perinatal Outcome After Premature Rupture of Membranes Completed NCT01538030
17 Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia Completed NCT02015247
18 Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios Recruiting NCT02901340
19 Sildenafil Citrate Therapy for Oligohydramnios Recruiting NCT02372487 sildenafil citrate
20 PPROM Registry (Preterm Premature Rupture of Membranes) Recruiting NCT02997345
21 Renal Agenesis Fetal Therapy Recruiting NCT03101891 Normal Saline, 0.9% injectable solution
22 A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine Recruiting NCT00833963 Trastuzumab;Pertuzumab;Ado-Trastuzumab Emtansine
23 Indomethacin PK and PD Therapy in Pregnancy Recruiting NCT02451228
24 Does Amniotic Fluid Index Affect the Fetal Cardiac Performance? Not yet recruiting NCT03277417
25 Hydrotherapy for the Reversal of Oligohydramnios Terminated NCT01682928 IV/Oral Hydration and Bedrest

Search NIH Clinical Center for Oligohydramnios

Cochrane evidence based reviews: oligohydramnios

Genetic Tests for Oligohydramnios

Genetic tests related to Oligohydramnios:

id Genetic test Affiliating Genes
1 Oligohydramnios 29

Anatomical Context for Oligohydramnios

MalaCards organs/tissues related to Oligohydramnios:

39
Lung, Placenta, Bone, Breast, Fetal Lung, Liver, Kidney

Publications for Oligohydramnios

Articles related to Oligohydramnios:

(show top 50) (show all 458)
id Title Authors Year
1
Perinatal outcomes in uncomplicated late preterm pregnancies with borderline oligohydramnios. ( 28782398 )
2017
2
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28277352 )
2017
3
A case of gestational central diabetes insipidus with oligohydramnios. ( 28764595 )
2017
4
Sildenafil Citrate Therapy for Oligohydramnios: A Randomized Controlled Trial. ( 28644321 )
2017
5
Report of a Triploid Fetus Identified in a Pregnancy with Oligohydramnios. ( 28459702 )
2017
6
MRI findings of chronic abruption-oligohydramnios sequence (CAOS): report of three cases. ( 28396921 )
2017
7
Oligohydramnios compromises lung cells size and interferes with epithelial-endothelial development. ( 28152278 )
2017
8
Obstetric outcomes of isolated oligohydramnios during early-term, full-term and late-term periods and determination of optimal timing of delivery. ( 27225520 )
2016
9
Are Major Depression and Generalized Anxiety Disorder Associated With Oligohydramnios in Pregnant Women? A Case-Control Study. ( 27357862 )
2016
10
Use of an Amnioport to Maintain Amniotic Fluid Volume in Fetuses with Oligohydramnios Secondary to Lower Urinary Tract Obstruction or Fetal Renal Anomalies. ( 27287190 )
2016
11
Aquaporin 3 Expression Induced by Salvia Miltiorrhiza via ERK1/2 Signal Pathway in the Primary Human Amnion Epithelium Cells from Isolated Oligohydramnios. ( 26917259 )
2016
12
Oligohydramnios and growth restriction do not portend worse prognosis in gastroschisis pregnancies. ( 26932657 )
2016
13
Induction of Labor in Women with Oligohydramnios: Misoprostol Compared with Prostaglandin E2. ( 27398704 )
2016
14
Significance of oligohydramnios in preterm small-for-gestational-age infants for outcome at 18 months of age. ( 27352940 )
2016
15
A randomized controlled study of the efficacy of 4 weeks of supplementation with I8-3 polyunsaturated fatty acids in cases of unexplained oligohydramnios. ( 27559716 )
2016
16
Pulmonary Hypoplasia Induced by Oligohydramnios: Findings from Animal Models and a Population-Based Study. ( 27324123 )
2016
17
Isolated Oligohydramnios at Term as an Indication for Labor Induction: A Systematic Review and Meta-Analysis. ( 27160748 )
2016
18
Role of l-Arginine in Oligohydramnios. ( 27651617 )
2016
19
Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. ( 27563258 )
2016
20
EP16.18: Outcome of the patients with late second trimester isolated oligohydramnios and echogenic bowel without evidence of premature rupture membranes. ( 27644197 )
2016
21
Oligohydramnios in complicated and uncomplicated pregnancies: a systematic review and meta-analysis. ( 27062200 )
2016
22
Lack of pharmacist-physician communication associated with nimesulide-induced oligohydramnios during pregnancy. ( 26951121 )
2016
23
Prostaglandin E2 induction of labor and cervical ripening for term isolated oligohydramnios in pregnant women with Bishop scoreA a8oA 5. ( 27745800 )
2016
24
Survival of fetuses with severe oligohydramnios. ( 27328487 )
2016
25
What does fetal autopsy unmask in oligohydramnios? ( 26381033 )
2015
26
Reversible oligohydramnios in the second trimester of pregnancy in two patients with long-term diclofenac exposure. ( 26318712 )
2015
27
Placental lesions associated with oligohydramnios in fetal growth restricted (FGR) pregnancies. ( 25735841 )
2015
28
Outcomes and management strategies in pregnancies with early onset oligohydramnios. ( 26152010 )
2015
29
An Update on Maternal Hydration Strategies for Amniotic Fluid Improvement in Isolated Oligohydramnios and Normohydramnios: Evidence from a Systematic Review of Literature and Meta-Analysis. ( 26658482 )
2015
30
Perinatal outcomes with isolated oligohydramnios at term pregnancy. ( 26506098 )
2015
31
Short-Term and Long-Term Postnatal Outcomes of Expectant Management After Previable Preterm Premature Rupture of Membranes With and Without Persistent Oligohydramnios. ( 26444125 )
2015
32
Feasibility and preliminary outcomes of fetoscopic laser photocoagulation for monochorionic twin gestation with selective intrauterine growth restriction accompanied by severe oligohydramnios. ( 26369752 )
2015
33
Important clinical information from successful treatment of a case with isolated severe oligohydramnios and deficient fetal growth late in the second trimester. ( 26384073 )
2015
34
Intra-vaginal prostaglandin E2 versus double-balloon catheter for labor induction in term oligohydramnios. ( 25275693 )
2014
35
Oligohydramnios sequence revisited in relationship to arthrogryposis, with distinctive skin changes. ( 25160497 )
2014
36
Severe midtrimester oligohydramnios: treatment strategies. ( 24614021 )
2014
37
Maternal hydration therapy improves the quantity of amniotic fluid and the pregnancy outcome in third-trimester isolated oligohydramnios. ( 24764350 )
2014
38
Decrease of the incidence of renin-angiotensin-system inhibitor induced oligohydramnios-sequence in Germany in 2011. ( 24633976 )
2014
39
Which is the safer method of labor induction for oligohydramnios women? Transcervical double balloon catheter or dinoprostone vaginal insert. ( 24397441 )
2014
40
Predictive value of second and third trimester fetal renal artery Doppler indices in idiopathic oligohydramnios and polyhydramnios in low-risk pregnancies: A longitudinal study. ( 25363086 )
2014
41
Oligohydramnios in women with preterm prelabor rupture of membranes and adverse pregnancy and neonatal outcomes. ( 25171293 )
2014
42
Perinatal outcomes in pregnancies with oligohydramnios after preterm premature rupture of membranes. ( 25283853 )
2014
43
The association between isolated oligohydramnios at term and pregnancy outcome. ( 24925346 )
2014
44
Adverse perinatal and neonatal outcomes in patients with chronic abruption-oligohydramnios sequence. ( 24888925 )
2014
45
Oligohydramnios in a pregnant Pakistani woman with Plasmodium vivax malaria. ( 24758193 )
2014
46
Therapeutic amnioinfusion for chronic abruption-oligohydramnios sequence: A possible prevention of the infant respiratory disease. ( 24428672 )
2014
47
Breech repositioning unresponsive to Webster technique: coexistence of oligohydramnios. ( 24294149 )
2013
48
Prenatal diagnosis of mosaic trisomy 2 associated with abnormal maternal serum screening, oligohydramnios, intrauterine growth restriction, ventricular septal defect, preaxial polydactyly, and facial dysmorphism. ( 24075380 )
2013
49
Amnioinfusion before 26 weeks' gestation for severe fetal growth restriction with oligohydramnios: Preliminary pilot study. ( 24245667 )
2013
50
Fetal swallowing as a protective mechanism against oligohydramnios and polyhydramnios in late gestation sheep. ( 22872543 )
2013

Variations for Oligohydramnios

ClinVar genetic disease variations for Oligohydramnios:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 TMEM67 NM_153704.5(TMEM67): c.1843T> C (p.Cys615Arg) single nucleotide variant Pathogenic/Likely pathogenic rs201893408 GRCh37 Chromosome 8, 94808198: 94808198
2 PKHD1 NM_138694.3(PKHD1): c.107C> T (p.Thr36Met) single nucleotide variant Pathogenic,protective rs137852944 GRCh37 Chromosome 6, 51947999: 51947999
3 TMEM67 NM_153704.5(TMEM67): c.1321C> T (p.Arg441Cys) single nucleotide variant Pathogenic/Likely pathogenic rs752362727 GRCh38 Chromosome 8, 93786255: 93786255

Expression for Oligohydramnios

Search GEO for disease gene expression data for Oligohydramnios.

Pathways for Oligohydramnios

GO Terms for Oligohydramnios

Cellular components related to Oligohydramnios according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.61 ACE AGTR1 AQP1 AQP3 CHRNA1 CHRND
2 postsynaptic membrane GO:0045211 9.33 CHRNA1 CHRND CHRNG
3 acetylcholine-gated channel complex GO:0005892 8.8 CHRNA1 CHRND CHRNG

Biological processes related to Oligohydramnios according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 excitatory postsynaptic potential GO:0060079 9.77 CHRNA1 CHRND CHRNG
2 regulation of blood pressure GO:0008217 9.76 ACE AGT REN
3 cation transmembrane transport GO:0098655 9.75 AQP1 CHRND CHRNG
4 regulation of postsynaptic membrane potential GO:0060078 9.7 CHRNA1 CHRND CHRNG
5 response to nicotine GO:0035094 9.69 CHRNA1 CHRND CHRNG
6 positive regulation of protein tyrosine kinase activity GO:0061098 9.67 ACE AGT
7 odontogenesis GO:0042476 9.66 AQP1 AQP3
8 renal water homeostasis GO:0003091 9.66 AQP1 AQP3
9 blood vessel remodeling GO:0001974 9.65 ACE AGT
10 positive regulation of reactive oxygen species metabolic process GO:2000379 9.65 AGT AGTR1
11 neuromuscular process GO:0050905 9.65 CHRNA1 CHRND
12 skeletal muscle contraction GO:0003009 9.64 CHRNA1 CHRND
13 water transport GO:0006833 9.64 AQP1 AQP3
14 positive regulation of cellular protein metabolic process GO:0032270 9.63 AGT AGTR1
15 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.63 AGT AGTR1
16 beta-amyloid metabolic process GO:0050435 9.62 ACE REN
17 regulation of blood vessel diameter GO:0097746 9.62 ACE AGTR1
18 low-density lipoprotein particle remodeling GO:0034374 9.61 AGT AGTR1
19 positive regulation of cholesterol esterification GO:0010873 9.61 AGT AGTR1
20 glycerol transport GO:0015793 9.59 AQP1 AQP3
21 synaptic transmission, cholinergic GO:0007271 9.58 CHRNA1 CHRND CHRNG
22 positive regulation of NAD(P)H oxidase activity GO:0033864 9.57 AGT AGTR1
23 musculoskeletal movement GO:0050881 9.56 CHRNA1 CHRND
24 regulation of renal sodium excretion GO:0035813 9.55 AGT AGTR1
25 renal water absorption GO:0070295 9.54 AQP1 AQP3
26 neuromuscular synaptic transmission GO:0007274 9.54 CHRNA1 CHRND CHRNG
27 regulation of vasoconstriction GO:0019229 9.5 ACE AGT AGTR1
28 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.49 AGT AGTR1
29 regulation of blood volume by renin-angiotensin GO:0002016 9.48 AGT REN
30 skeletal muscle tissue growth GO:0048630 9.46 CHRNA1 CHRND
31 regulation of renal output by angiotensin GO:0002019 9.43 ACE AGT
32 angiotensin maturation GO:0002003 9.43 ACE AGT REN
33 kidney development GO:0001822 9.35 ACE AGT AGTR1 PKHD1 REN
34 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.33 ACE AGT AGTR1
35 renin-angiotensin regulation of aldosterone production GO:0002018 8.8 AGT AGTR1 REN
36 transport GO:0006810 10.15 AFP AQP1 AQP3 CHRNA1 CHRND CHRNG

Molecular functions related to Oligohydramnios according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular ligand-gated ion channel activity GO:0005230 9.5 CHRNA1 CHRND CHRNG
2 ligand-gated ion channel activity GO:0015276 9.43 CHRNA1 CHRND CHRNG
3 acetylcholine receptor activity GO:0015464 9.4 CHRNA1 CHRNG
4 water channel activity GO:0015250 9.37 AQP1 AQP3
5 bradykinin receptor binding GO:0031711 9.16 ACE AGTR1
6 acetylcholine binding GO:0042166 9.13 CHRNA1 CHRND CHRNG
7 acetylcholine-gated cation-selective channel activity GO:0022848 8.8 CHRNA1 CHRND CHRNG

Sources for Oligohydramnios

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....